{"id":"citicoline-eye-drops-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Transient blurred vision"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Citicoline (cytidine 5'-diphosphocholine) is a precursor to phosphatidylcholine, a major component of cell membranes. When applied topically as eye drops, it penetrates ocular tissues and supports the synthesis and repair of damaged cell membranes, particularly in retinal and corneal cells. This mechanism helps restore cellular function and protect against degenerative processes in the eye.","oneSentence":"Citicoline is a naturally occurring compound that enhances cell membrane phospholipid synthesis and promotes neuronal membrane repair and protection in ocular tissues.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:08.253Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease"},{"name":"Corneal dystrophy"},{"name":"Retinal degenerative diseases"},{"name":"Post-operative corneal healing"}]},"trialDetails":[{"nctId":"NCT05710198","phase":"PHASE3","title":"Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma","status":"RECRUITING","sponsor":"Omikron Italia S.r.l.","startDate":"2023-12-11","conditions":"Glaucoma, Open-Angle","enrollment":1000},{"nctId":"NCT04003090","phase":"NA","title":"Citicoline Concentration in Human Vitreous","status":"COMPLETED","sponsor":"Istituto di Ricerca Neuroftalmologia S.r.l.","startDate":"2018-03-21","conditions":"Neurodegenerative Diseases","enrollment":26},{"nctId":"NCT03906513","phase":"NA","title":"Evaluation of the Efficacy of OMK2 in Recovering Corneal Neural Damage in Patients With Diabetes","status":"COMPLETED","sponsor":"University of Milan","startDate":"2017-05-03","conditions":"Cornea","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Citicoline eye drops 2%","genericName":"Citicoline eye drops 2%","companyName":"Omikron Italia S.r.l.","companyId":"omikron-italia-s-r-l","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Citicoline eye drops 2% is a small molecule intervention used in clinical trials for conditions such as cornea, neurodegenerative diseases, glaucoma, and open-angle glaucoma. Citicoline, also known as CDP-choline, is a compound that has been studied for its potential therapeutic effects in various conditions, including those related to the cornea and nervous system.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}